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CFSE  Carboxyfluorescein succinimidyl ester
CTLA-4  Cytotoxic T lymphocyte associated protein 4
FOXP3  Forkhead box P3
IL-21  Interleukin 21
TGFβ  Transforming growth factorβ
Treg  Regulatory T cell
Introduction
Immunosuppressive FOXP3+ regulatory T cells (Treg) are 
known to accumulate within the tumour microenvironment 
in a variety of cancers and are associated with deficiencies 
in effector T cell responses and poorer outcomes [1]. In 
gliomas, for example, Treg cells are found within tumour 
tissue and their accumulation correlates with advanced 
tumour stages [2–4]. The ratio of Treg cells to effector 
cell populations, such as CD8 T cells, also appears to be 
prognostically significant, with high CD8 T cell to Treg 
ratios being linked with more favourable outcomes in ovar-
ian cancers [5]. Moreover, in animal models of a number 
of different cancers, it has long been known that Treg cell 
depletion restores anti-tumour immunity and promotes 
tumour rejection [6–9]. Treg, therefore, represent a bar-
rier to effective natural anti-tumour immunity, but whether 
intra-tumoural Treg are recruited from existing periph-
eral populations or are induced to differentiate from naive 
CD4 T cells within the tumour microenvironment remains 
unclear. Both mechanisms likely play an important role and 
interestingly, both in vitro and in vivo CD4 T cell stimula-
tions with tumour antigens have been shown to induce Treg 
differentiation, even in the absence of other tumour-derived 
immunosuppressive factors [10, 11]. This has important 
implications not only within the tumour microenvironment, 
but also for anti-tumour immunotherapeutic strategies, such 
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as cancer vaccines and engineered chimeric antigen recep-
tor (CAR) T cells, where Treg induction would be counter-
productive and could significantly limit their potential.
In recent years, a number of cytokines have been found 
to inhibit regulatory T cell homeostasis and function, and 
thus may represent a route to alleviate Treg-mediated 
immunosuppression in cancer. In this respect, IL-21 has 
shown significant potential due to its ability to counteract 
the Treg-mediated inhibition of CD4 T cell responses in 
both murine [12, 13] and human studies [14]. This effect 
was found to be mediated indirectly by signaling to conven-
tional T cells [13, 15], and was associated primarily with 
diminished production of IL-2, a cytokine known to be 
essential for Treg survival [15]. IL-21 has also been demon-
strated to boost CD4 T cell responses via the upregulation 
of the co-stimulatory ligand CD86 on antigen-presenting 
cells [16], and is essential for the long-term maintenance of 
CD8 T cell function [17].
In the context of cancer, a crucial finding has been that 
IL-21 reduces the frequency of human FOXP3+ Treg cells 
by greater than 10-fold during tumour antigen stimula-
tions [10]. However, whether this represents inhibition of 
FOXP3 induction in naive CD4 T cells or curtailed expan-
sion of the natural Treg pool is not entirely clear. Moreover, 
it is not yet known whether IL-21 can maintain this effect 
in the presence of immunosuppressive tumour-derived fac-
tors, and if so, whether this is broadly applicable across 
tumour-types. In this study, we have investigated the ability 
of IL-21 to inhibit FOXP3 induction in purified naïve CD4 
T cells in the context of culture supernatants from a number 
of cancer cell lines. We show that, in the majority of cases, 
tumour-derived factors markedly promote Treg induction, 
particularly for those derived from colon cancers. Colon 
cancer cells also produced the highest levels of total and 
active TGFβ1, blockade of which prevented Treg induc-
tion. Similarly, IL-21 was able to inhibit tumour-mediated 
FOXP3 induction in naïve CD4 T cells and restore their 
proliferative capacity. Thus, in addition to its documented 
ability to prevent de novo Treg generation [18–20], IL-21 is 
able to maintain this effect in the context of tumour-derived 
milieus that actively promote FOXP3 expression.
Materials and methods
Ethics
Informed consent was obtained from all blood donors 
and the study was approved by an institutional ethics 
committee.
Cell lines
Five cell lines were used representing cancers of the colon 
(RKO, HCT116), lung (A549), liver (PLC/PRF-5) and 
brain (U87 MG). All cells were cultured in Dulbecco’s 
modified eagle’s medium (DMEM; Lonza) supplemented 
with 10% foetal bovine serum (Thermo Scientific), 2 mM 
l-Glutamine, 50  units/mL Penicillin and 50  g/mL Strep-
tomycin. Cells were incubated at 37 °C in a humidified 
atmosphere (5%  CO2). Culture supernatants were isolated 
from adherent cultures at days 3 or 4 and filtered through a 
cell strainer to remove cellular contamination prior to use 
in assays.
T cell isolation and culture
PBMCs were isolated from human peripheral blood by 
density gradient centrifugation over Histopaque (Sigma). 
Magnetic separation (StemCell Technologies) was then 
used to isolate naïve CD45RA+ CD4 T cells. Purified cells 
were cultured at 2.5 × 104 per well at a 1:1 ratio with CD3/
CD28 human T-activator beads (Gibco) for 5 days. Where 
indicated, cancer cell line culture supernatants were added 
as a fraction of the total volume of culture media (12.5, 25 
or 50%). For TGFβ blockade experiments, an anti-TGFβ 
antibody (1D11; R&D Systems) was used at 50  μg/mL. 
Where indicated, human recombinant IL-21 (Peprotech) 
was used at 200 ng/mL. At day 5, cells were harvested and 
analysed by flow cytometry. Cell counts are expressed as a 
percentage, with the cell count obtained for naïve T cells 
stimulated alone set at 100% (the maximal response).
Cultured suppressor assay
Purified naïve CD45RA+ CD4 T cells were cultured at 
2.5 × 104 per well at a 1:1 ratio with CD3/CD28 human 
T-activator beads (Gibco) for 5 days alone, in the presence 
of either 50% of the indicated cancer cell line supernatants 
or 200  ng/mL IL-21 (Peprotech), or with both. At day 5 
stimulator beads were removed magnetically and cells were 
washed 3 times with PBS before culture (as suppressors) 
with 2.5 × 104 freshly purified CFSE-labelled naïve CD4+ 
T cells from the same donor at a 2:1 ratio (cultured sup-
pressor T cells to freshly isolated naïve T cells). CD3/
CD28 human T-activator beads (Gibco) were again used 
at a 1:1 ratio. At day 5 cells were harvested and analysed 
by flow cytometry. Cell counts are expressed as a percent-
age, with the cell count obtained for CFSE-labelled naïve T 
cells incubated with control IL-21-stimulated suppressor T 
cells set at 100% (the maximal response).
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Flow cytometry
Cells were stained with monoclonal antibodies against CD4 
(RPA-T4; eBioscience), FOXP3 (236A/E7; eBioscience), 
CD25 (M-A251; BD Biosciences), CTLA-4 (BN13; BD 
Biosciences) and TGFβ (TW4-9E7; BD Biosciences). For 
intracellular staining, cells were fixed and permeabilised 
according to the manufacturer’s instructions (eBioscience). 
Stained cells were acquired using an Accuri C6 flow cytom-
eter (BD Biosciences) and data analysed using FlowJo soft-
ware (TreeStar). Statistical analyses were performed using a 
two-tailed paired t test with a 95% confidence interval. For 
the inverse correlation of FOXP3 expression with T cell pro-
liferation a simple linear regression analysis was performed.
TGFβ1 ELISA
Active TGFβ1 levels were determined using a sand-
wich ELISA according to the manufacturer’s instructions 
(eBioscience) and were derived from a standard curve of 
known TGFβ1 concentrations. To assay total TGFβ1 lev-
els, culture supernatants were incubated with 1N HCl for 
20  min before neutralization with 1N NaOH prior to the 
assay being performed. ELISA plates were read at 450 nm 
and absorbances for ELISA buffer alone controls were 
subtracted prior to analysis. Statistical analyses were per-
formed using a two-tailed unpaired t test with a 95% confi-
dence interval.
Fig. 1  Cancer-mediated induction of a Treg phenotype in naïve 
human CD4 T cells. a 2.5 × 104 CD45RA+ CD4+ T cells from 
human peripheral blood were stimulated with anti-CD3/28 antibody-
coated beads (1:1 ratio) alone or in the presence of 50% culture 
supernatant from the indicated cancer cell lines. After 5  days cells 
were stained with CD4 PE-Cy7, FOXP3 APC, CTLA-4 PE and CD25 
FITC for acquisition by flow cytometry. b Contour plots show expres-
sion of CD25 and CTLA-4 by gated CD4+ FOXP3+ cells. c Percent-
age of harvested CD4+ cells expressing FOXP3 across a titration of 
the indicated cancer supernatants. Data are representative of 4 inde-
pendent experiments. *P < 0.05; **P < 0.01; ***P < 0.001
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Results
To determine whether cancer cells are capable of directly 
inducing FOXP3 expression in naïve T cells, we purified 
CD45RA+ CD4 T cells from human peripheral blood and 
stimulated them for 5  days with anti-CD3/28 antibody-
coated beads, in the presence or absence of culture super-
natants from five cancer cell lines representing tumours 
of the colon, lung, liver and brain. We observed greatly 
enhanced FOXP3 induction in the presence of super-
natants from colon, lung and liver, but not brain cancer 
cells over that observed in their absence (Fig.  1a). These 
FOXP3 + cells also expressed other Treg phenotypic hall-
marks, including high levels of CD25 and the inhibitory 
receptor CTLA-4 (Fig.  1b). FOXP3 induction was titrat-
able, in that increasing the dose of cancer supernatant from 
12.5 to 25%, and again to 50% of the total culture media 
leads to greater increases in FOXP3 expression in the naïve 
T cells, particularly for supernatants representing colon 
cancers (Fig. 1c). In these same cultures T cell proliferation 
was also inhibited, in a dose-dependent manner, by super-
natants representing colon and lung, but not liver and brain 
cancers (Fig.  2a). Moreover, a significant inverse correla-
tion was observed between FOXP3 expression and T cell 
proliferation, such that increasing FOXP3 induction corre-
lated with inhibition of the T cell response (Fig. 2b).
As TGFβ1 has been shown to induce FOXP3 expression 
in naïve T cells [21, 22], we next determined whether our 
cancer cell lines expressed TGFβ1 by flow cytometry. Even 
in the absence of stimulation, basal TGFβ1 expression was 
observed in all five cell lines (Fig. 3a). To assess whether 
these cells subsequently secreted TGFβ1, we performed 
ELISAs assaying both active and, after acid-based release 
from its latent complex, total TGF β1. By this method, 
we found the highest concentrations of active and total 
TGFβ1 to be present in supernatants that induced the great-
est expression levels of FOXP3 expression in naïve T cells 
(Fig. 3b, c). To confirm this role for TGFβ1, we repeated 
our naïve T cell stimulations with cancer cell supernatants, 
in the context of TGFβ blockade mediated by a blocking 
anti-TGFβ antibody. In these assays, anti-TGFβ inhibited 
both the baseline FOXP3 induction observed in naïve T 
cells cultured alone, and that seen as a result of a 50% dose 
of cancer cell supernatants (Fig. 4a, b).
To determine whether IL-21 is capable of preventing 
tumour-mediated FOXP3 induction in naïve T cells, we 
repeated our naïve T cell stimulations in the presence of 
50% cancer cell supernatants, alone or with recombinant 
human IL-21. Similarly to TGFβ blockade, IL-21 was able 
to potently inhibit baseline FOXP3 induction in naïve T 
cells (Fig. 5a) and FOXP3 induction as a result of the addi-
tion of cancer cell supernatants (Fig.  5a, b). Accordingly, 
the addition of IL-21 to these cultures also counteracted 
the marked inhibition of T cell proliferation observed in the 
presence of supernatants from cell lines representing colon 
and lung cancers (Fig. 5c).
We next considered whether in the previous assay IL-21 
might be directly promoting T cell proliferation, rather than 
indirectly promoting T cell responses by limiting FOXP3 
induction. To address this, we repeated the cancer superna-
tant and IL-21 cultures described in Fig. 5, re-isolated the 
resultant T cells after 5 days, and assessed their ability to 
Fig. 2  Induction of FOXP3 correlates with inhibition of the naïve 
T cell response. a 2.5 × 104 CD45RA+ CD4+ T cells from human 
peripheral blood were stimulated with anti-CD3/28 antibody-coated 
beads (1:1 ratio) alone or in the presence of a titration of culture 
supernatant from the indicated cancer cell lines. After 5  days cells 
were stained with CD4 PE-Cy7 and FOXP3 APC for acquisition by 
flow cytometry. Histograms show CD4+ cell counts expressed as a 
proportion of the control naïve T cell count in the absence of cancer 
supernatant. b Inverse correlation between % FOXP3+ cells and T 
cell proliferation across all naïve T cell cultures with cancer super-
natants (P < 0.0001). Data are representative of 4 independent experi-
ments. *P < 0.05; **P < 0.01; ***P < 0.001
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suppress CFSE-labelled naïve T cells from the same donor. 
Because IL-21 was not added to the second T cell cultures, 
any increase in T cell proliferation observed could only be 
mediated indirectly by IL-21 signalling to the suppressor 
population in the first-round cultures. This assay also had 
the advantage of allowing us to determine whether cancer-
mediated acquisition of Treg characteristics was a stable 
phenotype. In these experiments, we observed inhibition of 
T cell responses consistent with the level of FOXP3 expres-
sion induced in the suppressor population by cancer cell 
supernatants (Fig. 6a, b). In accordance with its ability to 
inhibit FOXP3 expression, we observed significant restora-
tion in T cell proliferation and total cell counts when sup-
pressor populations were pre-incubated with IL-21.
Fig. 3  Induction of FOXP3 
in naïve T cells is linked with 
TGFβ1 secretion by cancer 
cells. a Indicated cancer cell 
lines were stained for intracel-
lular TGFβ1 expression and 
acquired by flow cytometry. 
b Total and c active TGFβ1 
concentrations for culture 
supernatants from the indicated 
cancer cell lines or media alone 
controls. Data are representative 
of 3–4 independent experi-
ments. *P < 0.05; **P < 0.01
Fig. 4  TGFβ1 blockade prevents cancer-mediated FOXP3 induction. 
a 2.5 × 104 CD45RA+ CD4+ T cells from human peripheral blood 
were stimulated with anti-CD3/28 antibody-coated beads (1:1 ratio) 
alone, with either 50% cancer cell culture supernatant or 50  μg/mL 
blocking anti-TGFβ antibody, or both. After 5 days cells were stained 
with FOXP3 APC and CD4 PE-Cy7 and acquired by flow cytometry. 
Representative contour plots are shown for cells cultured with RKO 
supernatant. b Histogram shows collated FOXP3+ CD4+ frequencies 
for these cultures. Data are representative of 3 independent experi-
ments. *P < 0.05; **P < 0.01; ***P < 0.001
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Discussion
Although the link between cancers and Treg induction has 
been previously investigated in murine studies [23], it has 
not been conclusively demonstrated in human cancers, 
wherein conventional CD4 T cells have been used, consist-
ing of both naïve and memory populations [24, 25]. Thus, 
there has until now remained doubt over whether increased 
expression of FOXP3 in human studies is due to the expan-
sion of pre-existing Treg populations, rather than de novo 
Treg generation. By sorting CD45RA+ naïve CD4 T cells 
in this study, our data reveal that a variety of cancers are 
able to directly mediate the differentiation of induced Treg 
from naïve human CD4 T cells.
Previous studies of FOXP3 induction in human CD4 
T cells have found that this does not necessarily confer 
immunosuppressive capacity, as FOXP3 is transiently 
expressed during the activation of non-suppressive effec-
tor cells [26–28]. Indeed, our own data show that during 
stimulations of naïve T cells in the absence of any cancer 
cell supernatant, around 30% of T cells upregulate FOXP3 
expression. In agreement with previous studies, these T 
cells were incapable of suppressing T cell responses in sub-
sequent cultures, suggesting that they had not acquired an 
immunoregulatory phenotype. In contrast, addition of can-
cer cell supernatants further increased FOXP3 expression 
in naïve T cells, and this increased expression correlated 
not only with T cell inhibition in the same cultures, but in 
subsequent cultures with freshly isolated naïve T cells.
It has long been known that exogenous TGFβ has the 
ability to induce Treg differentiation from naïve CD4 T 
cells [21, 22], and it has been suggested in a number of 
murine studies that this mechanism might be important 
during tumour-mediated Treg induction [29–31]. Indeed, in 
this study we found that all of the cancer cell lines stud-
ied expressed TGFβ1 to some extent. RKO cells were 
found to induce the greatest expression levels of FOXP3 
in naïve CD4 T cells, and blockade of TGFβ abrogated 
this effect, confirming the importance of this cytokine for 
tumour-mediated Treg induction in humans. Accordingly, 
U87 supernatants were found to contain significantly lower 
Fig. 5  IL-21 counteracts cancer-mediated FOXP3 induction and sup-
pression of naïve T cell proliferation. a 2.5 × 104 CD45RA+ CD4+ 
T cells from human peripheral blood were stimulated with anti-
CD3/28 antibody-coated beads (1:1 ratio) alone, with either 50% 
culture supernatant from the indicated cell lines or 200 ng/mL IL-21, 
or both. After 5 days cells were stained with FOXP3 APC and CD4 
PE-Cy7 and acquired by flow cytometry. b Histograms show col-
lated FOXP3+ CD4+ frequencies and c T cell proliferation data for 
these cultures. Data are representative of 4 independent experiments. 
*P < 0.05; **P < 0.01
▸
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levels of both active and total TGFβ1 than RKO superna-
tants, and did not induce FOXP3 expression or inhibit T 
cell proliferation. Previous studies of U87 supernatants 
have suggested an ability to induce FOXP3 expression, 
although these data were obtained using conventional T 
cells rather than purified naïve T cells [24]. Interestingly, 
despite differences in experimental approach, FOXP3 
induction appeared to be transient in this study and was not 
observed at day five, in agreement with our own data. Insta-
bility of FOXP3 induced by U87 supernatants would seem 
at odds with the demonstrated increased intratumoural Treg 
fractions found in glioma patients [2–4, 8]. However, it is 
important to note that some of these Treg might well be 
recruited natural Treg and that FOXP3-inducing factors 
within the tumour microenvironment would be continu-
ally expressed, and would, therefore, likely be sufficient to 
maintain stable FOXP3 expression in this setting.
The application of cytokines for cancer therapy has 
been extensively investigated and IL-2 has traditionally 
been thought to hold the greatest promise, stemming from 
its known capacity as a T cell growth factor. However, the 
discovery that IL-2 is critical for Treg survival and func-
tion [32–34] has raised serious concerns over its suitabil-
ity. Indeed, IL-2 administration has been shown to increase 
Treg numbers in cancer patients and in murine tumour 
models [35, 36]. These undesirable traits have led to a 
renewed interest in cytokines capable of selectively pro-
moting effector T cell responses, preferably whilst simul-
taneously inhibiting Treg-mediated immunosuppression. In 
these respects, IL-21 appears to be a far more appropriate 
candidate, not least because its administration to CD4 T 
cells drives their own responses and inhibits their ability to 
produce IL-2, depriving Treg cells of a non-redundant sur-
vival factor [15]. Unsurprisingly, a number of clinical trials 
of IL-21 administration in cancer therapy have now been 
initiated, either as a monotherapy or in combination with 
other agents [37].
In this study, we have assessed whether IL-21 is able to 
influence Treg induction in the setting of tumour-derived 
immunosuppressive factors. In this context, IL-21 acts 
a critical opposing force, specifically limiting tumour-
mediated FOXP3 induction and preventing suppression of 
the naïve T cell response. As such, these results confirm 
an important additional role for IL-21 in promoting anti-
tumour immunity. Thus, IL-21 should be effective regard-
less of whether intra-tumoural Treg are actively recruited 
natural Treg, in which case it would target their survival 
and function, or are induced within the tumour microenvi-
ronment, in which case it would target FOXP3 expression 
in naïve T cells. This two-pronged approach is, therefore, 
highly desirable, as it increases the likelihood of more com-
pletely restoring anti-tumour effector T cell responses. Our 
data also suggest that IL-21 could be beneficial as a thera-
peutic agent across a variety of cancers, due to its ability 
to inhibit FOXP3 induction across all the cancer cell lines 
tested.
Fig. 6  Cancer-mediated suppressor phenotype is maintained during 
subsequent T cell responses, and is counteracted by IL-21. a 2.5 × 104 
CD45RA+ CD4+ T cells from human peripheral blood were stimu-
lated with anti-CD3/28 antibody-coated beads (1:1 ratio) alone, with 
either 50% culture supernatant from the indicated cell lines or 200 ng/
mL IL-21, or both. After 5 days these suppressor cells were re-cul-
tured with 2.5 × 104 CFSE-labelled CD45RA+ CD4+ T cells from 
the same donor at a 2:1 ratio (suppressors to naïve cells), with anti-
CD3/28 antibody-coated beads at a 1:1 ratio. Representative contour 
plots show CFSE dilution for naïve T cells cultured with RKO or U87 
suppressors alone, or with these supernatants and IL-21. b Histogram 
shows collated CFSE+ CD4+ cell counts when cultured with sup-
pressors derived from the indicated cancer cell supernatant and IL-21 
cultures, expressed as a proportion of the control naïve T cell count in 
the absence of cancer supernatants. Data are representative of 4 inde-
pendent experiments. *P < 0.05; **P < 0.01; ***P < 0.001
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